Your session is about to expire
← Back to Search
PET Imaging for Pulmonary Arterial Hypertension
Phase < 1
Recruiting
Led By Stephen Chan
Research Sponsored by Stephen Y. Chan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Controls: Age between 18-75 years old
Cases: Age between 18-75 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 minutes
Awards & highlights
Study Summary
This trial will study whether [F-18]FGln can be used as a non-invasive imaging biomarker to detect early stages of pulmonary arterial hypertension (PAH), a disease affecting the blood vessels of the lung.
Who is the study for?
This trial is for adults aged 18-75 with confirmed PAH or at low risk of heart/lung diseases. It's not for pregnant/breastfeeding women, smokers, those with certain job exposures, CT contrast allergies, claustrophobia, excessive alcohol consumption, or conditions making the study unsafe.Check my eligibility
What is being tested?
[F-18]FGln PET imaging is being tested to see if it can non-invasively detect early stages of PAH by measuring glutamine metabolism in the lungs and heart. This could help diagnose PAH more quickly than current methods.See study design
What are the potential side effects?
As [F-18]FGln is used for imaging purposes and involves lying down in a scanner without medication administration like typical drugs, side effects are minimal but may include discomfort from staying still and potential reactions to the tracer substance.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 18 and 75 years old.
Select...
I am between 18 and 75 years old.
Select...
I have been diagnosed with a specific type of pulmonary hypertension or scleroderma without PAH, confirmed by heart catheterization.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 90 minutes
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 minutes
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
SUV or image-based threshold of 18F-FGNnon-diseased controls
Trial Design
1Treatment groups
Experimental Treatment
Group I: 18F-FGLN PET ImagingExperimental Treatment2 Interventions
10.0 mCi of 18F-FGln will be injected intravenously as a slow bolus (20 sec)
Find a Location
Who is running the clinical trial?
BayerIndustry Sponsor
2,238 Previous Clinical Trials
25,332,647 Total Patients Enrolled
28 Trials studying Pulmonary Arterial Hypertension
6,683 Patients Enrolled for Pulmonary Arterial Hypertension
Stephen Y. ChanLead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,836 Previous Clinical Trials
47,311,041 Total Patients Enrolled
25 Trials studying Pulmonary Arterial Hypertension
3,080 Patients Enrolled for Pulmonary Arterial Hypertension
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have claustrophobia.I have been exposed to radiation at work.I cannot lie down for long periods.You have had an allergic reaction to CT scan dye in the past.I cannot lie down for long periods.I am at low risk for heart or lung problems now or in the future.I am under 18 years old.You drink more than 2-3 alcoholic drinks per week.I am between 18 and 75 years old.You have worked in any of the occupations listed in the 'Occupation Exposure History' section.I am under 18 years old.You are a smoker.You have had an allergic reaction to CT scan dye in the past.You are a smoker.I have been exposed to radiation at work.You drink more than 2-3 alcoholic drinks per week.You have worked in any of the occupations listed in the 'Occupation Exposure History' section.You are afraid of small, enclosed spaces.I am between 18 and 75 years old.I have been diagnosed with a specific type of pulmonary hypertension or scleroderma without PAH, confirmed by heart catheterization.If you have any heart, lung, or other medical conditions that the principal investigator thinks would make it unsafe for you to be in the study.My family has a history of Pulmonary Hypertension or Scleroderma.
Research Study Groups:
This trial has the following groups:- Group 1: 18F-FGLN PET Imaging
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is the age restriction for this clinical trial above 35?
"The requirements for participation in this trial are that applicants must between 18 and 75 years old. This study includes 54 trials catering to minors, as well as a total of 662 studies for those aged 65 or above."
Answered by AI
Are there currently any recruitment opportunities for this clinical trial?
"Contrary to expectations, the clinical trial mentioned is not presently enrolling patients. The original post was made on November 1st 2022 while the most recent update occurred on October 10th 2022. Although this study may no longer be available, there are currently 749 other trials that require participants."
Answered by AI
May I register for participation in this experiment?
"This investigation is seeking 50 volunteers who are 18 to 75 years of age, diagnosed with SSc-PAH / SSc-eiPAH/IPAH/Scleroderma and have no PAH by right heart catheterization, as well as individuals who possess a low likelihood for developing cardiovascular or pulmonary ailments."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger